Jefferies Financial Group Inc. Increases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL)

Jefferies Financial Group Inc. lifted its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 104.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,600 shares of the company’s stock after buying an additional 20,200 shares during the quarter. Jefferies Financial Group Inc. owned about 0.06% of Personalis worth $229,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of PSNL. Blue Water Life Science Advisors LP lifted its position in Personalis by 13.3% in the fourth quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company’s stock valued at $6,548,000 after acquiring an additional 132,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Personalis by 144.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock valued at $2,372,000 after purchasing an additional 242,141 shares during the period. Jane Street Group LLC grew its stake in Personalis by 144.3% during the 4th quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock worth $2,320,000 after buying an additional 237,033 shares during the last quarter. abrdn plc acquired a new position in Personalis during the fourth quarter worth approximately $1,722,000. Finally, 683 Capital Management LLC purchased a new stake in Personalis in the fourth quarter valued at approximately $775,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Price Performance

Shares of NASDAQ PSNL opened at $4.95 on Monday. The stock has a fifty day moving average price of $3.76 and a 200 day moving average price of $4.45. Personalis, Inc. has a 1-year low of $1.14 and a 1-year high of $7.20. The company has a market cap of $437.21 million, a PE ratio of -2.95 and a beta of 1.83.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $20.61 million during the quarter, compared to analysts’ expectations of $17.41 million. Analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PSNL. HC Wainwright raised their target price on shares of Personalis from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, May 7th. Craig Hallum began coverage on shares of Personalis in a research report on Monday, March 17th. They set a “buy” rating and a $8.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Finally, Guggenheim started coverage on shares of Personalis in a research note on Thursday. They set a “buy” rating and a $6.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $7.67.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.